A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Started June 16, 2018
32
Resurrecting response to ruxolitinib: A Phase I study of ruxolitinib and umbralisib (TGR-1202) in ruxolitinib-experienced myelofibrosis
Started June 16, 2018
52
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy
Started June 16, 2018
33
TG-1701 is a novel, orally available and covalently bound BTK inhibitor
Started June 15, 2018
69
Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid Malignancies
Started June 15, 2018
30
TG-1601 is a Novel BET Inhibitor with Strong Binding Affinity and Long-lasting Effect in Pre-clinical Models
Started April 18, 2018
68
Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study
Started February 20, 2018
79
PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation
Started December 11, 2017
42
An Integrated Safety Analysis of the Next Generation PI3K Delta Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
Started December 11, 2017
31
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Started December 11, 2017
27
Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model
Started December 10, 2017
35
Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas
Started December 10, 2017
41